Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus VOYXACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus VOYXACT.
ARRANON vs VOYXACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
GABAA receptor positive allosteric modulator; a neuroactive steroid that potentiates GABAergic inhibition.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
Adults: 200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal elimination half-life approximately 37 hours (range 24-51 hours), supporting once-daily dosing with steady-state achieved in 5-8 days.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Primarily hepatic metabolism via CYP3A4, with 53% of the dose excreted in feces (mainly as metabolites) and 27% in urine (mostly as metabolites); less than 1% excreted unchanged in urine.
Category C
Category C
Antineoplastic
Antineoplastic